Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update

Published: Aug 08, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LAWRENCEVILLE, N.J., Aug. 8, 2013 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial results for the second quarter ended June 30, 2013 and an update from its retrospective analysis of the clinical trial results for ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news